A systems biology approach to identify novel biomarkers and causative pathways in patients with psoriatic arthritis

A systems biology approach to identify novel biomarkers and causative pathways in patients with psoriatic arthritis - From psoriasis to arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45190

Enrollment

900

Registered

2014-05-14

Start date

2014-10-02

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriatic arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with psoriasis, psoriatic arthritis, ankylosing spondylitis (AS), inflammatory bowel disease associated arthritis, reactive arthritis, or undifferentiated spondyloarthritis.

Exclusion criteria

Exclusion criteria: -age 17 years or younger - age 76 years or older -The patient has an alternative inflammatory rheumatological diagnosis (e.g. rheumatoid arthritis, gout, pseudogout).

Design outcomes

Primary

Measure	Time frame
Clinical endpoints: Diagnosis (conform CASPAR criteria), disease activity and treatment response (conform the composite scores DAS28, ACR, and CPDAI). For details see section 8.1.1. of the study protocol. Laboratory endpoints: the transcriptome (RNA sequencing), the epigenome (micro RNA profiling and genome-wide methylation) and the proteome in white blood cells derived from the blood samples collected throughout follow-up. The frequency, phenotype, and function of the white blood cells will be quantified. For details see section 8.2.1. and 8.4.7 of the study protocol.	—

Measure

Time frame

Clinical endpoints: Diagnosis (conform CASPAR criteria), disease activity and treatment response (conform the composite scores DAS28, ACR, and CPDAI). For details see section 8.1.1. of the study protocol. Laboratory endpoints: the transcriptome (RNA sequencing), the epigenome (micro RNA profiling and genome-wide methylation) and the proteome in white blood cells derived from the blood samples collected throughout follow-up. The frequency, phenotype, and function of the white blood cells will be quantified. For details see section 8.2.1. and 8.4.7 of the study protocol.

—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results